MC2 Therapeutics A/S
http://www.mc2therapeutics.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From MC2 Therapeutics A/S
Scrip Asks…What Does 2024 Hold For Biopharma? Part 6: Therapeutic Area Advances
More than 100 biopharma executives and experts told Scrip their predictions for therapeutic area advances in the coming year. The recent commercial success of GLP-1s in diabetes and obesity and their potential in further disease areas fuelled excitement around the metabolic space. Expectations were also positive in neurology following the launch of Leqembi for Alzheimer’s disease in 2023, while the multiple opportunities to improve cancer treatment kept oncology top of the pile overall.
Deal Watch: Bayer Ties Up With Twist On Optimization Of Antibody Discovery
Plus deals involving Advanz/Dimerix, Boehringer Ingelheim/Zeiss Medical Technology, Roche/Ionis, Kriya/Everads and updates from the world of technology transfer.
Asia Deal Watch: US Biotech LIB Partners In Greater China With Hasten On PCSK9 Therapy
Plus deals involving Astellas/Menarini, Maruho/Fortress Biotech, Zenas/Bristol Myers Squibb, Huadong Medicine/MC2 and more.
Almirall Plots M&A Moves Ahead Of Lebrikizumab Approval
The Spanish group has been fairly quiet on the dealmaking front of late but the proceeds of a significant capital raise have been earmarked to help “swiftly execute inorganic growth opportunities.”
Company Information
- Industry
-
Pharmaceuticals
-
Drug Delivery
- Topical Delivery
-
Drug Delivery
- Other Names / Subsidiaries
-
- MC2 Biotek, Drug Delivery Solutions Ltd.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice